Claims for Patent: 9,353,171

Summary for Patent: 9,353,171

Title:	Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs for treating contrast-induced nephropathy
Abstract:	Featured are methods and compositions for treating, managing, preventing, or reducing injury to the kidney of a mammal (e.g., a human) caused by one or more iodinated radiocontrast media. The methods include administering an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds, which includes native human PACAP38, native human PACAP27, native human vasoactive intestinal peptide (VIP), their agonists, analogs, fragments, and derivatives, with activities toward one or more of the PACAP/VIP receptors, including all of their various isoforms. Also provided are pharmaceutical compositions of one or more PACAP-like compounds, either alone or in combination with one or more other prophylactic/therapeutic agents useful for treating, managing, or preventing injury to the kidney of a mammal (e.g., a human) undergoing treatment with one or more iodinated radiocontrast media. Also featured is an in vivo mouse model for testing the efficacy of cytoprotective agents against contrast-induced nephropathy.
Inventor(s):	Batuman; Vecihi (New Orleans, LA), Maderdrut; Jerome L. (New Orleans, LA), Li; Min (New Orleans, LA), Coy; David H. (New Orleans, LA)
Assignee:	The Administrators of the Tulane Educational Fund (New Orleans, LA)
Application Number:	14/357,393
Patent Claims:	1. A method for treating, managing, preventing, or reducing an injury to a kidney of a mammal resulting from administration of an iodinated radiocontrast medium comprising administering to said mammal in need thereof an effective amount of at least one pituitary adenylate cyclase-activating polypeptide (PACAP)-like compound having at least 90% sequence identity to an amino acid sequence selected from any one of SEQ ID NOs: 1-76, wherein the PACAP-like compound treats, manages, prevents, or reduces said injuries to the kidney. 2. The method of claim 1, wherein said PACAP-like compound is administered at a dose in the range of 1 .mu.g to 1 gram or wherein said administering achieves a concentration of 10.sup.-14 M to 10.sup.-6 of the PACAP-like compound in the blood of the mammal. 3. The method of claim 1, wherein said PACAP-like compound is administered by intravenous infusion, intraperitoneal injection, subcutaneous injection, transcutaneous administration, intramuscular injection, aerosol administration, intranasal administration, or oral administration. 4. The method of claim 1, wherein said method comprises administering said PACAP-like compound one or more times per day, week, month, or year. 5. The method of claim 1, wherein the PACAP-like compound is administered in combination with a cytoprotective agent, a vasodilator, or a vasoconstrictor antagonist. 6. The method of claim 5, wherein the cytoprotective agent is selected from the group consisting of ascorbic acid, vitamin E, mesna, palifermin, erythropoietin, apocynin, diphenylene iodonium, pentoxifylline, etanercept, simvastatin, amifostine, dexrazoxane, and N-acetylcysteine. 7. The method of claim 5, wherein the vasodilator is selected from the group consisting of fenoldopam, atrial natriuretic peptide, theophylline, and aminophylline; or wherein the vasoconstrictor antagonist is SB 209670. 8. The method of claim 1, wherein the PACAP-like compound reduces the severity of an anaphylactic reaction caused by said iodinated radiocontrast medium. 9. The method of claim 1, wherein the mammal is being treated with the iodinated radiocontrast medium in conjunction with a diagnostic and/or interventional procedure. 10. The method of claim 9, wherein the diagnostic and/or interventional procedure is selected from the group consisting of angiography, urography, pyelography, arthrography, cholangiography, diskography, myelography, contrast-enhanced computer tomography, and cerebral ventriculography. 11. The method of claim 10, wherein the angiography is cardiac angiography. 12. The method of 1, wherein said iodinated radiocontrast medium is selected from the group consisting of iobitridol, iodipamide, iodixanol, iohexol, iomeprol, iopamidol, iopentol, iopromide, iotrolan, ioversol, ioxilan, iothalamate, ioxithalamate, ioxaglate, metrizamide, acetrizoate, metrizoate, and diatrizoate. 13. The method of claim 1, wherein said PACAP-like compound is administered to said mammal after administration of said iodinated radiocontrast medium. 14. The method of claim 1, wherein said PACAP-like compound is administered to said mammal before administration of said iodinated radiocontrast medium. 15. The method of claim 1, wherein said PACAP-like compound comprises an amino acid sequence selected from any one of SEQ ID NOs:1-76. 16. The method of claim 1, wherein said mammal is a human, cow, lamb, pig, horse, cat, dog, rat, monkey, rabbit, mouse, or guinea pig.

Details for Patent 9,353,171

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2031-11-17
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2031-11-17
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2031-11-17
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2031-11-17
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017		2031-11-17
Immunex Corporation	ENBREL	etanercept	Injection	103795			2031-11-17
Immunex Corporation	ENBREL	etanercept	Injection	103795	03/05/2020		2031-11-17